82 related articles for article (PubMed ID: 8572640)
1. Usefulness of lymphocyte subset change as an indicator for predicting survival time and effectiveness of treatment with the immunopotentiator lentinan.
Matsuoka H; Yano K; Seo Y; Saito T; Tomoda H; Tsurumoto S
Anticancer Res; 1995; 15(5B):2291-6. PubMed ID: 8572640
[TBL] [Abstract][Full Text] [Related]
2. Lentinan potentiates immunity and prolongs the survival time of some patients.
Matsuoka H; Seo Y; Wakasugi H; Saito T; Tomoda H
Anticancer Res; 1997; 17(4A):2751-5. PubMed ID: 9252710
[TBL] [Abstract][Full Text] [Related]
3. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
Steingrimsdottir H; Gruber A; Björkholm M; Svensson A; Hansson M
Haematologica; 2000 Aug; 85(8):832-8. PubMed ID: 10942930
[TBL] [Abstract][Full Text] [Related]
4. Modulation of peripheral blood lymphocyte subsets during methylprednisolone pulse therapy.
Fukuda R; Horiki T; Sasao T; Kawada H; Ichikawa Y
Tokai J Exp Clin Med; 1996 Jun; 21(2):77-88. PubMed ID: 9239809
[TBL] [Abstract][Full Text] [Related]
5. Comparative immunophenotypic features of EBV-positive and EBV-negative atypical lymphocytosis.
Hudnall SD; Patel J; Schwab H; Martinez J
Cytometry B Clin Cytom; 2003 Sep; 55(1):22-8. PubMed ID: 12949956
[TBL] [Abstract][Full Text] [Related]
6. [Studies on usefulness of postoperative adjuvant chemotherapy with lentinan in patients with gastrointestinal cancer].
Tanabe H; Imai N; Takechi K
Nihon Gan Chiryo Gakkai Shi; 1990 Aug; 25(8):1657-67. PubMed ID: 2230448
[TBL] [Abstract][Full Text] [Related]
7. Effects of oral lentinan on T-cell subsets in peripheral venous blood.
Hanaue H; Tokuda Y; Machimura T; Kamijoh A; Kondo Y; Ogoshi K; Makuuchi H; Nakasaki H; Tajima T; Mitomi T
Clin Ther; 1989; 11(5):614-22. PubMed ID: 2529966
[TBL] [Abstract][Full Text] [Related]
8. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
Lauria F; Raspadori D; Ventura MA; Rondelli D; Zinzani PL; Gherlinzoni F; Miggiano MC; Fiacchini M; Rosti G; Rizzi S; Tura S
Bone Marrow Transplant; 1996 Jul; 18(1):79-85. PubMed ID: 8831999
[TBL] [Abstract][Full Text] [Related]
9. NK cell activity in the presence of IL-12 is a prognostic assay to neoadjuvant chemotherapy in cervical cancer.
Cosiski Marana HR; Santana da Silva J; Moreira de Andrade J
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):318-23. PubMed ID: 10985887
[TBL] [Abstract][Full Text] [Related]
10. Lymphocyte subsets in the course of continuous ambulatory peritoneal dialysis.
Grzegorzewska AE; Leander M
Adv Perit Dial; 2001; 17():10-4. PubMed ID: 11510253
[TBL] [Abstract][Full Text] [Related]
11. [Pilot study of TS-1 combined with lentinan in patients with unresectable or recurrent advanced gastric cancer].
Nimura H; Mitsumori N; Tsukagoshi S; Nakajima M; Atomi Y; Suzuki S; Kusano M; Yoshiyuki T; Tokunaga A
Gan To Kagaku Ryoho; 2003 Sep; 30(9):1289-96. PubMed ID: 14518408
[TBL] [Abstract][Full Text] [Related]
12. A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group.
Nakano H; Namatame K; Nemoto H; Motohashi H; Nishiyama K; Kumada K
Hepatogastroenterology; 1999; 46(28):2662-8. PubMed ID: 10522061
[TBL] [Abstract][Full Text] [Related]
13. [TS-1/CDDP/Lentinan combination chemotherapy for inoperable advanced gastric cancer].
Nagahashi S; Suzuki H; Nishiwaki M; Okuda K; Kurosawa Y; Terada S; Sugihara T; Andou K; Hibi T
Gan To Kagaku Ryoho; 2004 Nov; 31(12):1999-2003. PubMed ID: 15570928
[TBL] [Abstract][Full Text] [Related]
14. Dysregulation of blood lymphocyte subsets and natural killer cells in schistosomal liver cirrhosis and hepatocellular carcinoma.
Attallah AM; Tabll AA; El-Sadany M; Ibrahim TA; El-Dosoky I
Clin Exp Med; 2003 Nov; 3(3):181-5. PubMed ID: 14648234
[TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of anti-tumor effects of Lentinan combined with chemotherapy in the treatment of various malignancies.
Qing ZJ; Ming QX; Zhong TF
Gan To Kagaku Ryoho; 1997 May; 24 Suppl 1():1-8. PubMed ID: 9210882
[No Abstract] [Full Text] [Related]
16. [Effects of endoscopic intratumoral injection of lentinan in patients with gastric cancer].
Inagaki T; Morise K; Matsunaga H
Gan To Kagaku Ryoho; 1988 Feb; 15(2):319-24. PubMed ID: 3257678
[TBL] [Abstract][Full Text] [Related]
17. Lentinan has a stimulatory effect on innate and adaptive immunity against murine Listeria monocytogenes infection.
Kupfahl C; Geginat G; Hof H
Int Immunopharmacol; 2006 Apr; 6(4):686-96. PubMed ID: 16504933
[TBL] [Abstract][Full Text] [Related]
18. Partial review of immunotherapeutic pharmacology in stem cell transplantation.
Bierman PJ; Abe F; Buyukberber S; Ino K; Talmadge JE
In Vivo; 2000; 14(1):221-36. PubMed ID: 10757081
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic changes in lymphocyte subpopulations in pediatric renal-transplant patients after T-cell depletion.
Klaus G; Mostert K; Reckzeh B; Mueller TF
Transplantation; 2003 Dec; 76(12):1719-24. PubMed ID: 14688522
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma.
Isoda N; Eguchi Y; Nukaya H; Hosho K; Suga Y; Suga T; Nakazawa S; Sugano K
Hepatogastroenterology; 2009; 56(90):437-41. PubMed ID: 19579616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
